Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. Evidence From a Clopidogrel-to-Ticlopidine Crossover Study

Journal of the American College of Cardiology

Volumn 50, Issue 12, 2007, Pages 1132-1137

  Campo, Gianluca ^a   Valgimigli, Marco ^a,b   Gemmati, Donato ^c   Percoco, Gianfranco ^a   Catozzi, Linda ^c   Frangione, Alice ^a   Federici, Federica ^c   Ferrari, Fabrizio ^a   Tebaldi, Matteo ^a   Luccarelli, Serena ^a   Parrinello, Giovanni ^d   Ferrari, Roberto ^a,b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PYRIDINE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROBABILITY; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 34548497430     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.092     Document Type: Article

References (21)

1. Bertrand M.E., Rupprecht H.J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
2. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
3. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
4. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
5. Ajzenberg N., Aubry P., Huisse M.G., et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 45 (2005) 1753-1756
6. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J Am Coll Cardiol 46 (2005) 1827-1832
7. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting. J Am Coll Cardiol 46 (2005) 1820-1826
8. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
9. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
10. Bertrand M., Simoons M., Fox K., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 23 (2002) 1809-1840
11. Campo G., Valgimigli M., Gemmati D., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 48 (2006) 2178-2185
12. Jernberg T., Payne C.D., Winters K.J., et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27 (2006) 1166-1173
13. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol 96 (2005) 1095-1099
14. Angiolillo D.J., Bernardo E., Ramirez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
15. Angiolillo D.J., Shoemaker S.B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
16. Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
17. Aleil B., Rochoux G., Monassier J.P., Cazenave J.P., and Gachet C. Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. J Thromb Haemost 4 (2006) 1-3
18. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
19. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108 (2006) 2244-2247
20. Alfonso F., and Angiolillo D. Platelet function assessment to predict outcomes after coronary interventions. Hype or hope?. J Am Coll Cardiol 48 (2006) 1751-1754
21. Gurbel P.A., and Bliden K.P. Durability of platelet inhibition by clopidogrel. Am J Cardiol 91 (2003) 1123-1125